Abstract
Acridine derivatives are interesting chemotherapeutic agents that were first used as antibacterial and antiparasite agents. In this review we wish to concentrate our attention on the anticancer properties of acridines used in clinics since the 1970s. Based on recent results, an outlook on antitumour acridine chemotherapy will be proposed. The biological activity of acridines is mainly attributed to the planarity of these aromatic structures, which can intercalate within the double-stranded DNA structure, thus interfering with the cellular machinery. Recent understanding of the mode of action of acridines leads to continuous and exciting research in this heterocyclic family. Indeed, biological targets such as topoisomerases I and II, telomerase/telomere and protein kinases emerge and allow the design of novel acridine-based patterns. This review further pinpoints the latest progress in the development of anticancer agents based on naturally occurring and synthetic acridines (e.g. acridones, pyridoacridines); for this matter in vitro/in vivo studies and clinical trial results will be discussed. The DNA-affinic property of acridine is also useful to vectorise drugs into cell nuclei and some applications in hypoxia-selective treatment, platinum or N-mustard derived conjugates will be reported. Some other properties including inhibition of multidrug resistance or potential impact on Alzheimer disease will be treated. It is noteworthy that the position and the nature of the substituent on the heterocyclic core are determinants for the biological property and selectivity observed. So, we wish also to disclose a summary of recent synthetic methodologies developed for acridine synthesis.
Keywords: Acridine, acridone, alkaloid, anticancer, antitumour, topoisomerases, telomerase, hypoxia, organic synthesis
Anti-Cancer Agents in Medicinal Chemistry
Title: Acridine and Acridone Derivatives, Anticancer Properties and Synthetic Methods: Where Are We Now?
Volume: 7 Issue: 2
Author(s): Philippe Belmont, Johann Bosson, Thomas Godet and Martin Tiano
Affiliation:
Keywords: Acridine, acridone, alkaloid, anticancer, antitumour, topoisomerases, telomerase, hypoxia, organic synthesis
Abstract: Acridine derivatives are interesting chemotherapeutic agents that were first used as antibacterial and antiparasite agents. In this review we wish to concentrate our attention on the anticancer properties of acridines used in clinics since the 1970s. Based on recent results, an outlook on antitumour acridine chemotherapy will be proposed. The biological activity of acridines is mainly attributed to the planarity of these aromatic structures, which can intercalate within the double-stranded DNA structure, thus interfering with the cellular machinery. Recent understanding of the mode of action of acridines leads to continuous and exciting research in this heterocyclic family. Indeed, biological targets such as topoisomerases I and II, telomerase/telomere and protein kinases emerge and allow the design of novel acridine-based patterns. This review further pinpoints the latest progress in the development of anticancer agents based on naturally occurring and synthetic acridines (e.g. acridones, pyridoacridines); for this matter in vitro/in vivo studies and clinical trial results will be discussed. The DNA-affinic property of acridine is also useful to vectorise drugs into cell nuclei and some applications in hypoxia-selective treatment, platinum or N-mustard derived conjugates will be reported. Some other properties including inhibition of multidrug resistance or potential impact on Alzheimer disease will be treated. It is noteworthy that the position and the nature of the substituent on the heterocyclic core are determinants for the biological property and selectivity observed. So, we wish also to disclose a summary of recent synthetic methodologies developed for acridine synthesis.
Export Options
About this article
Cite this article as:
Belmont Philippe, Bosson Johann, Godet Thomas and Tiano Martin, Acridine and Acridone Derivatives, Anticancer Properties and Synthetic Methods: Where Are We Now?, Anti-Cancer Agents in Medicinal Chemistry 2007; 7 (2) . https://dx.doi.org/10.2174/187152007780058669
DOI https://dx.doi.org/10.2174/187152007780058669 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Genomic Approaches to Major Depression
Current Pharmacogenomics Bioinformatics Studies on Induced Pluripotent Stem Cell
Current Bioinformatics Pleiotropic Effects of Glucagon-like Peptide-1 (GLP-1)-Based Therapies on Vascular Complications in Diabetes
Current Pharmaceutical Design Machine Learning Techniques and Drug Design
Current Medicinal Chemistry New Challenges in CNS Repair: The Immune and Nervous Connection
Current Immunology Reviews (Discontinued) Agents Targeting Prostate Cancer Bone Metastasis
Anti-Cancer Agents in Medicinal Chemistry Generation, Subsets and Functions of Inducible Regulatory T Cells
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Differences in Sexual Risk Behaviors Between Lower and Higher Frequency Alcohol-Using African-American Adolescent Females
Current HIV Research Crosstalk between Behavior and Immune System During the Prodromal Stages of Alzheimer`s Disease
Current Pharmaceutical Design TRPV1 Antagonists as a Potential Treatment for Hyperalgesia
Recent Patents on CNS Drug Discovery (Discontinued) Competitive Intelligence Tools for University-Based Technology Transfer Offices
Technology Transfer and Entrepreneurship (Discontinued) The Pathogenic Role of Persistent Milk Signaling in mTORC1- and Milk- MicroRNA-Driven Type 2 Diabetes Mellitus
Current Diabetes Reviews Rationalizing the Study of Plants for the Treatment of Oral Pain
Current Chemical Biology Imaging of Sigma1 Receptors in the Human Brain Using PET and [11C]SA4503
Central Nervous System Agents in Medicinal Chemistry Structural Alterations of the Retinal Microcirculation in the “Prehypertensive” High- Normal Blood Pressure State
Current Pharmaceutical Design Brain Endothelial Cell-Cell Junctions: How to “Open” the Blood Brain Barrier
Current Neuropharmacology Metabolism of Nicotine and 4-(methylnitrosamino)-l-(3-pyridyl)-lbutanone (NNK) in Menthol and Non-menthol Cigarette Smokers
Drug Metabolism Letters Tau PET Distributional Pattern in AD Patients with Visuospatial Dysfunction
Current Alzheimer Research An Overview of Piperazine Scaffold as Promising Nucleus for Different Therapeutic Targets
Current Pharmaceutical Design Glycine Transporter 1 Inhibitors and Modulation of NMDA Receptor-Mediated Excitatory Neurotransmission
Current Drug Targets